Fri, Feb 28, 10:10 PM (56 days ago)
**Cryo-Cell International, Inc. (CCEL) Summary:** For the fiscal year ending November 30, 2024, Cryo-Cell International reported a revenue of $31,986,106, reflecting a 2% increase from $31,343,695 in 2023. The growth was driven by a 4% rise in recurring storage fees, although new specimen processing decreased by 6%. Net income stood at $402,095, a recovery from a net loss of $9,521,669 the previous year. Operating expenses rose by 8% to $28,505,822, primarily due to increased selling and administrative costs. The company's strategic focus includes expanding its core business via the Duke License Agreement, which has faced legal challenges, resulting in a $13,108,064 asset impairment in 2023. Future investments related to this agreement are on hold pending arbitration with Duke. The company anticipates a cash requirement of over $50 million for related activities, with liquidity sufficient for the next 12 months, although this is contingent on resolving the Duke dispute. Key risk factors include competitive pressures in the stem cell market, regulatory challenges, and the impact of ongoing legal disputes. As of November 30, 2024, Cryo-Cell's total assets were $64,677,633, with a stockholders' deficit of $13,216,017.